University of Alberta

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1908-01-01

Employees: 10K

Market Cap: -

Website: http://www.ualberta.ca

Clinical Trials

Synbiotics and Post-op Crohn's Disease

Not Applicable

Terminated

Conditions: Crohn's Disease

Interventions: Other: Digestible Maltodextrin
Dietary Supplement: Synbiotic

First Posted Date: 2021-03-18

Last Posted Date: 2024-01-19

Lead Sponsor: University of Alberta

Target Recruit Count: 4

Registration Number: NCT04804046

Locations: 🇨🇦
Misericordia Community Hospital, Edmonton, Alberta, Canada
🇨🇦
Grey Nuns Community Hospital, Edmonton, Alberta, Canada
🇨🇦
University of Alberta Human Nutrition Research Unit, Edmonton, Alberta, Canada

and more 2 locations

Corticosteroids for COVID-19

Phase 3

Withdrawn

Conditions: Covid19

Interventions: Drug: Prednisone
Device: Point of Care testing device for C-reactive protein

First Posted Date: 2021-03-12

Last Posted Date: 2022-04-14

Lead Sponsor: University of Alberta

Registration Number: NCT04795583

Locations: 🇨🇴
Clinica de la Mujer, Bogotá, Colombia
🇲🇽
ABC Medical Center, Mexico City, Mexico

Online Wellness Intervention for Primary Biliary Cholangitis (PBC)

Not Applicable

Completed

Conditions: Primary Biliary Cirrhosis

Interventions: Behavioral: Mind-body therapy

First Posted Date: 2021-03-10

Last Posted Date: 2024-01-18

Lead Sponsor: University of Alberta

Target Recruit Count: 34

Registration Number: NCT04791527

Locations: 🇨🇦
University of Alberta, Edmonton, Alberta, Canada

Antibiotic Prophylaxis for Neurogenic Bladder Botox

Phase 2

Not yet recruiting

Conditions: Neurogenic Bladder
Post-operative Urinary Tract Infections

Interventions: Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2021-03-10

Last Posted Date: 2024-12-17

Lead Sponsor: University of Alberta

Target Recruit Count: 160

Registration Number: NCT04791579

18F-PSMA-1007 PET/CT Imaging in Patients With Biochemically Recurrent or High-risk Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Diagnostic Test: 18F-PSMA-1007

First Posted Date: 2021-02-02

Last Posted Date: 2023-11-27

Lead Sponsor: University of Alberta

Target Recruit Count: 100

Registration Number: NCT04733768

Locations: 🇨🇦
University of Alberta, Edmonton, Alberta, Canada

Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19

Completed

Conditions: Covid19
Dyspnea

Interventions: Other: No Intervention

First Posted Date: 2021-02-01

Last Posted Date: 2024-05-08

Lead Sponsor: University of Alberta

Target Recruit Count: 64

Registration Number: NCT04732663

Locations: 🇨🇦
Clinical Physiology Laboratory, Edmonton, Alberta, Canada

Biomarkers of Mortality and Morbidity in Children Hospitalized With Fever

Completed

Conditions: Fever

First Posted Date: 2021-01-27

Last Posted Date: 2021-01-27

Lead Sponsor: University of Alberta

Target Recruit Count: 2500

Registration Number: NCT04726826

Locations: 🇺🇬
Jinja Regional Referral Hospital, Jinja, Uganda

Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis

Phase 2

Completed

Conditions: Appendicitis Acute

First Posted Date: 2021-01-22

Last Posted Date: 2024-03-12

Lead Sponsor: University of Alberta

Target Recruit Count: 42

Registration Number: NCT04717193

Locations: 🇨🇦
Stollery Children's Hospital, Edmonton, Alberta, Canada

Trifecta-Heart cfDNA-MMDx Study

Recruiting

Conditions: Heart Transplant Rejection

Interventions: Diagnostic Test: MMDx diagnostic test
Diagnostic Test: Prospera
Diagnostic Test: HLA antibody

First Posted Date: 2021-01-13

Last Posted Date: 2024-10-24

Lead Sponsor: University of Alberta

Target Recruit Count: 300

Registration Number: NCT04707872

Locations: 🇺🇸
Baptist Health Institute for Research and Innovation, Little Rock, Arkansas, United States
🇺🇸
Columbia University Medical Center, Columbia Interventional Cardiovascular Care, W. New York, New Jersey, United States
🇺🇸
Montefiore Medical Center, 3319 Rochambeau Avenue, 2nd FL, Bronx, New York, United States

and more 8 locations

18F-DOPA II - PET Imaging Optimization

Phase 3

Recruiting

Conditions: Congenital Hyperinsulinism
Brain Tumor
Neuroblastoma
Neuroendocrine Tumors
Parkinson Disease
Lewy Body Disease

Interventions: Drug: 18F-DOPA
Drug: Furosemide Injection

First Posted Date: 2021-01-13

Last Posted Date: 2024-04-22

Lead Sponsor: University of Alberta

Target Recruit Count: 800

Registration Number: NCT04706910

Locations: 🇨🇦
WC Mackenzie Health Science Centre / University of Alberta Hospital, Edmonton, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy